PR Newswire
YOKNEAM, Israel, Nov. 12, 2020 /PRNewswire/ — InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, today announced consolidated financial results for its third quarter ended September 30, 2020.
Third Quarter 2020 Highlights:
- Record quarterly revenues of $59.7 million, an increase of 49% compared to the third quarter of 2019; approximately 58% of quarterly revenues derived from InMode’s proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments, approximately 35% of quarterly revenues derived from InMode’s recently introduced hands-free platforms and approximately 7% derived from InMode’s traditional laser and non-invasive RF platforms
- Record GAAP net income of $23.9 million, compared to $16.2 million in the third quarter of 2019; *non-GAAP net income of $26.6 million, compared to $16.5 million in the third quarter of 2019
- Record GAAP diluted earnings per share of $0.57 compared to $0.42 in the third quarter of 2019; *non-GAAP diluted earnings per share of $0.63 compared to $0.42 in the third quarter of 2019
- Total cash position of $234.3 million as of September 30, 2020, including cash and cash equivalents, marketable securities and short-term bank deposits
|
(U.S. dollars in thousands, except for per share data) |
||
|
|
|
|
|
Revenues |
$59,714 |
$40,010 |
|
Gross Margins |
84% |
87% |
|
Net Income Attributable to InMode Ltd. |
$23,895 |
$16,186 |
|
Earnings per Diluted Share |
$0.57 |
$0.42 |
|
|
||
|
|
|
|
|
Gross Margins |
85% |
87% |
|
Net Income Attributable to InMode Ltd. |
$26,638 |
$16,512 |
|
Earnings per Diluted Share |
$0.63 |
$0.42 |
*Please refer to “Use of Non-GAAP Financial Measures” below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.
Management Comments
“Our record third quarter revenues were driven by the success of our minimally invasive and hands-free solutions in the United States and internationally, strengthening the leading market position of our harnessed electro-surgical technologies. The steadfast sales & marketing investments we made throughout the pandemic enabled our organization to quickly meet surging demand as restrictions loosened,” commented Moshe Mizrahy, InMode’s CEO.
“During the quarter, we continued to focus on research & development and were excited to announce the launch of the Morpheus8 Body handpiece and Morpheus8 Platform. We understand that the uncertainties of the COVID-19 pandemic are not behind us, and we will remain committed to the health of our employees and our organization,” commented Dr. Michael Kreindel, InMode’s CTO and co-founder.
“We believe the steps we took over the last several months were instrumental in building interest, increased awareness and demand for InMode technologies, which translated into record sales in the third quarter. We believe we are emerging as the standard of care for minimally invasive aesthetic surgeries, as we continue to innovate and deliver versatile offerings. We expect continued underlying demand for our differentiated products heading into the fourth quarter of 2020,” commented Shakil Lakhani, President of North America.
2020 Guidance
We expect that our revenues for the full year of 2020 will be between $192 million and $195 million, and we expect to maintain a *non-GAAP gross margin of 84%-86%.
This outlook is not a guarantee of future performance and stockholders should not rely on such forward-looking statements. See “Forward-Looking Statements” for additional information.
Third Quarter 2020 Financial Results
Total revenues for the third quarter of 2020 were $59.7 million, an increase of 49% as compared to the third quarter of 2019. The increase in revenues was driven primarily by the expansion of InMode’s direct sales organization in the United States and the continued momentum of InMode’s hands-free technology, as well as the recently introduced Morpheus8 Body fractional technology. Moreover, InMode continued to gain traction in international markets, with international revenues growing 109% year-over-year.
GAAP gross margin for the third quarter of 2020 was 84% compared to a gross margin of 87% in the third quarter of 2019. *Non-GAAP gross margin for the third quarter of 2020 was 85% compared to a gross margin of 87% in the third quarter of 2019. This decrease is primarily attributable to the increase of sales in international markets, mainly in countries where we operate through distributors.
GAAP operating margin for the third quarter of 2020 was 39%, compared to 40% in the third quarter of 2019. *Non-GAAP operating margin for the third quarter of 2020 was 43%, compared to 41% in the third quarter of 2019. This increase in *non-GAAP operating margin was primarily attributable to decreased marketing activities in the United States such as event and conference participation, due to restrictions caused by the COVID-19 pandemic.
InMode reported GAAP net income attributable to InMode Ltd. of $23.9 million, or $0.57 per diluted share in the third quarter of 2020 compared to $16.2 million, or $0.42 per diluted share, in the third quarter of 2019. On a *non-GAAP basis, InMode reported net income attributable to InMode Ltd. of $26.6 million, or $0.63 per diluted share in the third quarter of 2020 compared to $16.5 million, or $0.42 per diluted share, in the third quarter of 2019.
“We ended the third quarter with a strong balance sheet and record results. Our measured approach of investing for the future while maintaining flexibility during the COVID-19 pandemic has paid off this quarter,” noted Yair Malca, InMode’s CFO. “During the quarter, we announced a share repurchase program of up to one million of InMode’s shares, which reflects our unwavering faith in InMode’s success.”
*Please refer to “Use of Non-GAAP Financial Measures” below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided following the financial statements that are included in this release. Non-GAAP results exclude share-based compensation and related tax adjustments.
Use of Non-GAAP Financial Measures
In addition to InMode’s operating results presented in accordance with GAAP, this release includes certain non-GAAP financial measures including non-GAAP net income, non-GAAP diluted earnings per share and non-GAAP operating margin. Because these measures are used in InMode’s internal analysis of financial and operating performance, management believes that they provide greater transparency to investors of management’s view of InMode’s economic performance. Management also believes the presentation of these measures, when analyzed in conjunction with InMode’s GAAP operating results, allows investors to more effectively evaluate and compare the performance of InMode to that of its peers, although InMode’s presentation of its non-GAAP measures may not be comparable to other similarly-titled measures of other companies. Schedules reconciling each of these non-GAAP financial measures are provided as a supplement to this release.
Conference Call Information
Mr. Moshe Mizrahy, Chairman and Chief Executive Officer, Dr. Michael Kreindel, co-founder and Chief Technology Officer, Mr. Yair Malca, Chief Financial Officer, Mr. Shakil Lakhani, President of North America, and Dr. Spero Theodorou, Chief Medical Officer, will host a conference call today, November 12, 2020, at 8:30 a.m. Eastern Time to discuss the third quarter 2020 financial results.
The Company encourages participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10148536/da3e5e2fe8. Callers will receive a unique dial-in upon registration, which enables immediate access to the call. Participants may pre-register at any time, including up to and after the call start time.
For callers that opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call ten minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.
U.S. Toll-Free Dial-in Number: 1-866-777-2509
Israel Toll– Free Dial-in Number: 1-80-921-2373
International Dial-in Number: 1-412-317-5413
At:
8:30 a.m. Eastern Time
5:30 a.m. Pacific Time
3:30 p.m. Israel Time
The conference call will also be webcast live from a link on InMode’s website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from November 12, 2020 at 12 p.m. Eastern Time to November 26, 2020 at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers:
Replay Dial-in U.S TOLL-FREE: 1-877-344-7529
Replay Dial-in Canada TOLL-FREE: 855-669-9658
Replay Dial-in TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 10148536
A replay will also be available for 90 days on InMode’s website at https://inmodemd.com/investors/.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio-frequency (“RF”) technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
Forward-Looking Statements
The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode’s future financial or operating performance, including the future performance described above under the heading titled “2020 Guidance.” Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would” and similar expressions that concern our expectations, strategy plans or intentions. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including with respect to the impact of the COVID-19 global outbreak. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode’s Annual Report on Form F-20 filed with the Securities and Exchange Commission on February 18, 2020, risk factors relating to the COVID-19 global outbreak and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
|
Company Contact: Yair Malca Chief Financial Officer Phone: (949) 305-0108 Email: [email protected] |
Investor Relations Contact: Miri Segal MS-IR LLC Phone: (917) 607-8654 Email: [email protected] |
|
|
||||
|
CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
||||
|
(U.S. dollars in thousands, except for per share data) |
||||
|
(Unaudited) |
||||
|
|
|
|||
|
|
|
|
|
|
|
|
59,714 |
40,010 |
130,920 |
109,359 |
|
|
9,395 |
5,047 |
20,274 |
14,193 |
|
|
|
|
|
|
|
|
||||
|
Research and development |
1,959 |
1,329 |
7,207 |
4,112 |
|
Sales and marketing |
23,758 |
16,726 |
61,293 |
46,721 |
|
General and administrative |
1,309 |
927 |
4,745 |
2,693 |
|
|
27,026 |
18,982 |
73,245 |
53,526 |
|
|
|
|
|
|
|
Finance income, net |
798 |
479 |
2,063 |
1,264 |
|
|
|
|
|
|
|
|
207 |
267 |
509 |
718 |
|
|
|
|
|
|
|
Add: Loss (net income) attributable to non-controlling interests |
11 |
(7) |
(39) |
(79) |
|
|
|
|
|
|
|
|
||||
|
Basic |
0.65 |
0.53 |
1.09 |
1.50 |
|
Diluted |
0.57 |
0.42 |
0.93 |
1.15 |
|
|
||||
|
Basic |
36,697 |
30,297 |
35,542 |
28,031 |
|
Diluted |
42,082 |
39,004 |
41,894 |
36,654 |
|
|
||
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
||
|
(U.S. dollars in thousands, except for per share data) |
||
|
(Unaudited) |
||
|
|
|
|
|
|
||
|
|
||
|
Cash and cash equivalents |
68,835 |
44,727 |
|
Marketable securities |
122,046 |
120,144 |
|
Short-term bank deposits |
43,436 |
28,491 |
|
Accounts receivable, net of allowance for doubtful accounts |
16,164 |
6,628 |
|
Other receivables |
4,790 |
3,810 |
|
Inventories |
14,871 |
9,408 |
|
|
270,142 |
213,208 |
|
|
||
|
Accounts receivable |
455 |
374 |
|
Deferred income taxes, net |
606 |
1,899 |
|
Operating lease right-of-use assets |
1,282 |
1,369 |
|
Property and equipment, net |
1,056 |
935 |
|
Other investments |
600 |
600 |
|
|
3,999 |
5,177 |
|
|
274,141 |
218,385 |
|
|
||
|
|
||
|
Accounts payable |
4,283 |
3,702 |
|
Contract liabilities |
15,671 |
15,587 |
|
Other liabilities |
17,572 |
13,205 |
|
|
37,526 |
32,494 |
|
|
||
|
Contract liabilities |
2,069 |
3,813 |
|
Other liabilities |
1,969 |
1,494 |
|
Operating lease liabilities |
519 |
744 |
|
Deferred income taxes, net |
32 |
37 |
|
|
4,589 |
6,088 |
|
|
42,115 |
38,582 |
|
|
232,026 |
179,803 |
|
|
274,141 |
218,385 |
|
|
|||||
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||
|
(U.S. dollars in thousands, except for per share data) |
|||||
|
(Unaudited) |
|||||
|
|
|
||||
|
|
|
|
|
||
|
|
|||||
|
Net income |
23,884 |
16,193 |
38,955 |
42,186 |
|
|
Adjustments required to reconcile net income to net cash provided by operating activities: |
|||||
|
Depreciation and amortization |
108 |
77 |
307 |
214 |
|
|
Share-based compensation expenses |
2,404 |
385 |
9,614 |
1,199 |
|
|
Allowance for doubtful accounts |
– |
55 |
466 |
133 |
|
|
Loss on marketable securities, net |
11 |
– |
2 |
– |
|
|
Finance income, net |
(279) |
(86) |
(11) |
(395) |
|
|
Deferred income taxes, net |
347 |
(68) |
1,173 |
(211) |
|
|
Changes in operating assets and liabilities: |
|||||
|
Increase in accounts receivable |
(7,628) |
(2,324) |
(10,083) |
(597) |
|
|
Decrease (increase) in other receivables |
537 |
(1,814) |
(960) |
(650) |
|
|
Decrease (increase) in inventories |
1,356 |
(879) |
(5,463) |
(1,532) |
|
|
Increase in accounts payable |
257 |
689 |
581 |
759 |
|
|
Increase in other liabilities |
4,187 |
2,402 |
4,717 |
2,418 |
|
|
Increase (decrease) in contract liabilities |
5,010 |
(1,115) |
(1,660) |
1,263 |
|
|
Decrease in accrued contingencies |
– |
– |
– |
(10,000) |
|
|
Net cash provided by operating activities |
30,194 |
13,515 |
37,638 |
34,787 |
|
|
|
|||||
|
Investment in short-term deposit |
(18,090) |
(17,220) |
(49,699) |
(34,310) |
|
|
Proceeds from short-term deposit |
6,720 |
8,500 |
34,810 |
18,500 |
|
|
Purchase of fixed assets |
(103) |
(54) |
(428) |
(518) |
|
|
Purchase of marketable securities |
(41,085) |
(68,282) |
(119,394) |
(82,621) |
|
|
Proceeds from sale of marketable securities |
25,500 |
13,500 |
117,786 |
18,103 |
|
|
Net cash (used in) investing activities |
(27,058) |
(63,556) |
(16,925) |
(80,846) |
|
|
|
|||||
|
Proceeds from initial public offering of ordinary shares, net of offering costs |
– |
69,784 |
– |
69,784 |
|
|
Exercise of options |
698 |
178 |
3,248 |
315 |
|
|
Net cash provided by financing activities |
698 |
69,962 |
3,248 |
70,099 |
|
|
|
234 |
(93) |
147 |
(56) |
|
|
|
4,068 |
19,828 |
24,108 |
23,984 |
|
|
|
64,767 |
28,877 |
44,727 |
24,721 |
|
|
|
68,835 |
48,705 |
68,835 |
48,705 |
|
|
|
||||
|
CONDENSED CONSOLIDATED FINANCIAL HIGHLIGHTS |
||||
|
(U.S. dollars in thousands, except for per share data) |
||||
|
(Unaudited) |
||||
|
|
|
|||
|
|
|
|
|
|
|
|
||||
|
United States |
40,880 |
31,007 |
95,763 |
87,813 |
|
International |
18,834 |
9,003 |
35,157 |
21,546 |
|
|
59,714 |
40,010 |
130,920 |
109,359 |
|
U.S. as percentage of total revenue |
68% |
77% |
73% |
80% |
|
|
||||||
|
RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF |
||||||
|
INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
||||||
|
(U.S. dollars in thousands, except for per share data) |
||||||
|
(Unaudited) |
||||||
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
59,714 |
– |
59,714 |
40,010 |
– |
40,010 |
|
|
9,395 |
(155) |
9,240 |
5,047 |
(21) |
5,026 |
|
|
50,319 |
155 |
50,474 |
34,963 |
21 |
34,984 |
|
|
||||||
|
Research and development |
1,959 |
(124) |
1,835 |
1,329 |
(58) |
1,271 |
|
Sales and marketing |
23,758 |
(1,974) |
21,784 |
16,726 |
(270) |
16,456 |
|
General and administrative |
1,309 |
(151) |
1,158 |
927 |
(36) |
891 |
|
|
27,026 |
(2,249) |
24,777 |
18,982 |
(364) |
18,618 |
|
|
23,293 |
2,404 |
25,697 |
15,981 |
385 |
16,366 |
|
Finance income, net |
798 |
– |
798 |
479 |
– |
479 |
|
|
24,091 |
2,404 |
26,495 |
16,460 |
385 |
16,845 |
|
|
207 |
(339) |
(132) |
267 |
59 |
326 |
|
|
23,884 |
2,743 |
26,627 |
16,193 |
326 |
16,519 |
|
Add: Loss (net income) attributable to non-controlling interests |
11 |
– |
11 |
(7) |
– |
(7) |
|
|
23,895 |
2,743 |
26,638 |
16,186 |
326 |
16,512 |
|
|
||||||
|
Basic |
0.65 |
0.73 |
0.53 |
0.55 |
||
|
Diluted |
0.57 |
0.63 |
0.42 |
0.42 |
||
|
|
||||||
|
Basic |
36,697 |
36,697 |
30,297 |
30,297 |
||
|
Diluted |
42,082 |
42,289 |
39,004 |
39,047 |
||
|
|
||||||
|
RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF |
||||||
|
INCOME TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF INCOME |
||||||
|
(U.S. dollars in thousands, except for per share data) |
||||||
|
(Unaudited) |
||||||
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
130,920 |
– |
130,920 |
109,359 |
– |
109,359 |
|
|
20,274 |
(380) |
19,894 |
14,193 |
(62) |
14,131 |
|
|
110,646 |
380 |
111,026 |
95,166 |
62 |
95,228 |
|
|
||||||
|
Research and development |
7,207 |
(2,132) |
5,075 |
4,112 |
(166) |
3,946 |
|
Sales and marketing |
61,293 |
(6,569) |
54,724 |
46,721 |
(887) |
45,834 |
|
General and administrative |
4,745 |
(533) |
4,212 |
2,693 |
(84) |
2,609 |
|
|
73,245 |
(9,234) |
64,011 |
53,526 |
(1,137) |
52,389 |
|
|
37,401 |
9,614 |
47,015 |
41,640 |
1,199 |
42,839 |
|
Finance income, net |
2,063 |
– |
2,063 |
1,264 |
– |
1,264 |
|
|
39,464 |
9,614 |
49,078 |
42,904 |
1,199 |
44,103 |
|
|
509 |
(763) |
(254) |
718 |
227 |
945 |
|
|
38,955 |
10,377 |
49,332 |
42,186 |
972 |
43,158 |
|
Add: Loss (net income) attributable to non-controlling interests |
(39) |
– |
(39) |
(79) |
– |
(79) |
|
|
38,916 |
10,377 |
49,293 |
42,107 |
972 |
43,079 |
|
|
||||||
|
Basic |
1.09 |
1.39 |
1.50 |
1.53 |
||
|
Diluted |
0.93 |
1.17 |
1.15 |
1.17 |
||
|
|
||||||
|
Basic |
35,542 |
35,542 |
28,031 |
28,031 |
||
|
Diluted |
41,894 |
42,061 |
36,654 |
36,707 |
||
View original content:SOURCE InMode Ltd.
